Clinical Trials Logo

Clinical Trial Summary

The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease. Another important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study. Participants will: - Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information. - Be asked study-related questions by phone or at a clinic visit. - Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year/s including new test results, treatment information, symptoms, and complications from HHT.


Clinical Trial Description

The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is a research initiative led by the HHT Foundation International, Inc. ("Cure HHT"). The study focuses on Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder characterized by the development of abnormal blood vessels in various organs of the body, including the brain, spine, lungs, liver, GI tract, skin, nasal mucosa, and oral cavity. The prevalence of HHT is estimated to be 1 in 5000, affecting children and adults. These abnormal blood vessels can lead to acute and chronic bleeding, stroke, heart failure, and death. Treatments are currently predominately limited to managing complications, while approximately 90% of adults have ongoing symptoms, despite the best surgical and medical therapies. With recent drug developments related to angiogenesis, there is hope for effective novel therapies. A natural history registry for HHT has significant implications for improving the understanding and management of this rare genetic disorder. The purpose of this study is to better understand HHT, the symptoms and complications it causes ("outcomes"), and to understand how the disease impacts people's lives. The investigators hypothesize that a natural history registry for HHT will improve our understanding of the disease, lead to better management of patients, and ultimately, contribute to developing novel therapies to treat this disease. The investigators will collaborate with multiple HHT Centers of Excellence across the U.S. to establish a comprehensive registry of HHT patients. The study aims to enroll approximately 10,000 HHT patients over a 10-year period. Longitudinal data will be collected both retrospectively and prospectively, with a focus on increasing the understanding of this rare disease, accelerating the development of new diagnostic and treatment options, and working collaboratively with clinicians who care for individuals with HHT to identify and address gaps in the system of care, especially those from underserved populations. The study aims to serve as a centralized resource for future clinical trials and research in HHT. Data security and confidentiality are prioritized, and participants have the option to withdraw from the study at any time. The study is funded by the U.S. Department of Health Resources and Service Administration (HRSA) through a grant awarded to Cure HHT. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06259292
Study type Observational [Patient Registry]
Source Cure HHT
Contact Melissa A Dickey, MSN
Phone 410-357-9932
Email melissa.dickey@curehht.org
Status Recruiting
Phase
Start date November 13, 2023
Completion date November 2033

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05060731 - Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding Phase 4
Recruiting NCT05949268 - Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel
Not yet recruiting NCT03243240 - Computed Tomography in Gastrointestinal Bleeding N/A
Completed NCT02595853 - Efficacy of a Novel Hemostatic Powder in GI Bleeding
Completed NCT01434108 - Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding Phase 2/Phase 3
Terminated NCT01756690 - Predicting Lung Injury From Transfusion in Patients With Liver Disease N/A
Completed NCT01424254 - The Effectiveness of Video-capsule Endoscopy in Gastrointestinal Bleeding of Obscure Origin Phase 3
Completed NCT05884931 - Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment N/A
Completed NCT01335516 - Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices N/A
Withdrawn NCT00401908 - Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding N/A
Recruiting NCT05024864 - HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in MI Patients N/A
Completed NCT05008640 - Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
Completed NCT03716466 - Evaluation of Prophylactic Endotracheal Intubation
Completed NCT05362227 - High-Volume Vs Low-Volume Preparation in Emergency Department N/A
Completed NCT02405286 - Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage N/A
Recruiting NCT00562445 - Adrenal Insufficiency in Critical Emergencies in Digestive Diseases N/A
Recruiting NCT05290857 - Anticoagulation After GI Bleeding Pilot Study and Registry N/A
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry
Completed NCT01415869 - Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients
Completed NCT01821326 - Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding N/A